A New Dawn in the Fight Against Malaria: Why This Breakthrough Matters

GanLum, the first new malaria drug in decades, shows over 99% cure rates in Phase III trials. Learn how this breakthrough treatment by Novartis could transform global malaria control, fight rising drug resistance, and accelerate elimination efforts in Africa and South Asia.

RESEARCH & INNOVATION